CareyHwangMDPhD
Infectious Disease • Skillman, NJHIV/AIDS Medicine
Senior Vice President, Clinical Research, Head of Chronic Infection - Vir Biotechnology
Dr. Hwang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
241 Sunset Rd
Skillman, NJ 08558Phone+1 415-992-6293
Education & Training
Vanderbilt University Medical CenterFellowship, Infectious Disease, 2005 - 2009- Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2005
West Virginia University School of MedicineClass of 2003
Certifications & Licensure
TN State Medical License 2004 - 2019
Clinical Trials
- HIV Resistance and Treatment Strategies Start of enrollment: 2007 Jan 01
Publications & Presentations
PubMed
- 2 citationsChronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.Marion G Peters, Man-Fung Yuen, Norah Terrault, John Fry, Pietro Lampertico
Clinical Infectious Diseases. 2024-04-10 - 9 citationsBrief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receivi...Jean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, Christopher Bettacchi, Carolina Chahin Anania
Journal of Acquired Immune Deficiency Syndromes. 2022-09-01 - 7 citationsDoravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.Ming-Tain Lai, Meizhen Feng, Min Xu, Winnie Ngo, Tracy L Diamond
Antimicrobial Agents and Chemotherapy. 2022-05-17
Journal Articles
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases
Press Mentions
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus InfectionSeptember 22nd, 2022- Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver ConferenceJune 27th, 2022
- Vir Biotechnology Announces New Clinical Data from Its Broad Hepatitis B ProgramJune 27th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
